LATE-BREAKING ABSTRACT: A phase 2a study of benralizumab in adults with COPD

C. Brightling, M. Bafadhel, E. Bleecker, R. Panettieri, D. She, C. K Ward, X. Xu, R. van der Merwe (Leicester, Oxford, Cambridge, United Kingdom; Winston-Salem, Philadelphia, Gaithersburg, United States Of America)

Source: International Congress 2014 – Latest insights in airway diseases
Session: Latest insights in airway diseases
Session type: Thematic Poster Session
Number: 2818
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Brightling, M. Bafadhel, E. Bleecker, R. Panettieri, D. She, C. K Ward, X. Xu, R. van der Merwe (Leicester, Oxford, Cambridge, United Kingdom; Winston-Salem, Philadelphia, Gaithersburg, United States Of America). LATE-BREAKING ABSTRACT: A phase 2a study of benralizumab in adults with COPD. Eur Respir J 2014; 44: Suppl. 58, 2818

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

LATE-BREAKING ABSTRACT: A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014


LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene
Source: International Congress 2014 – COPD exacerbations
Year: 2014


LATE-BREAKING ABSTRACT: The Guangzhou COPD exacerbation study: relationship of exacerbations with viral infections and soluble biomarkers
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014


LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015

LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014

LATE-BREAKING ABSTRACT: Corticosteroid responsiveness in COPD
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016


LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015


LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016


LATE-BREAKING ABSTRACT: Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: The copenhagen general population study
Source: International Congress 2015 – New observations in respiratory epidemiology
Year: 2015

LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014

LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS)
Source: International Congress 2016 – Best abstracts in asthma and COPD
Year: 2016

Development of a human COPD model-on-a-chip to mimic disease exacerbation (a small airway-on-a-chip model)
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016


Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

LATE-BREAKING ABSTRACT: Eosinophilic inflammation in COPD: During clinical stability and exacerbations. The AERIS study
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015


Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


LATE-BREAKING ABSTRACT: Microbiology and radiology of pneumonia in COPD
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015

Outcomes of immunotherapy of patients with COPD
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014